


Biomarkers for tumor immune therapy associated neurological side effects



PRINCIPAL INVESTIGATORS:
Prof. Dr. Matthias Endres, PD. Dr. Wolfgang Böhmerle, Dr. Samuel Knauss, Dr. Leonie Müller-Jensen, PD Dr. Petra Hühnchen
Charité



SUMMARY

Tumor immunotherapy and in particular immune checkpoint inhibitor treatment continues to transform oncological therapy and the number of patients treated with checkpoint inhibitors is expected to increase substantially in the coming years. High response rates to the treatment are contrasted by potentially fatal immune related adverse events (irAE). Albeit neurological irAE (irAE-N) are rare, they are associated with high morbidity and mortality.

This projects aims at identifying immunological biomarkers to identify irAR-N in patients treated with immune checkpoint inhibitors. The increased surveillance of patients with a risk profile will affect patient's treatment and reduce the cost of care as well as mortality and morbidity associated with the treatment.

PROJECT GOALS

- Identify biomarkers for irAE-N
- File patent

LONG-TERM GOALS

- Cooperation with Medtech company / Start-up foundation
- Implementation of identified biomarkers in clinical practice